WO2008096127A3 - Bicyclo[2.2.1]hept-7-ylamine derivatives and their use as m3 muscarinic receptor modulators - Google Patents

Bicyclo[2.2.1]hept-7-ylamine derivatives and their use as m3 muscarinic receptor modulators Download PDF

Info

Publication number
WO2008096127A3
WO2008096127A3 PCT/GB2008/000405 GB2008000405W WO2008096127A3 WO 2008096127 A3 WO2008096127 A3 WO 2008096127A3 GB 2008000405 W GB2008000405 W GB 2008000405W WO 2008096127 A3 WO2008096127 A3 WO 2008096127A3
Authority
WO
WIPO (PCT)
Prior art keywords
hept
bicyclo
receptor modulators
muscarinic receptor
ylamine derivatives
Prior art date
Application number
PCT/GB2008/000405
Other languages
French (fr)
Other versions
WO2008096127A2 (en
Inventor
Lilian Alcaraz
Nicholas Kindon
Jonathan Mark Sutton
Original Assignee
Argenta Discovery Ltd
Astrazeneca Ab
Lilian Alcaraz
Nicholas Kindon
Jonathan Mark Sutton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenta Discovery Ltd, Astrazeneca Ab, Lilian Alcaraz, Nicholas Kindon, Jonathan Mark Sutton filed Critical Argenta Discovery Ltd
Publication of WO2008096127A2 publication Critical patent/WO2008096127A2/en
Publication of WO2008096127A3 publication Critical patent/WO2008096127A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention provides compounds of formula (I) having muscarinic M3 receptor and β-adrenergic receptor modulating activity; processes for their preparation and their use in therapy; wherein A, R1, R2, R3 and R4 are defined herein.
PCT/GB2008/000405 2007-02-07 2008-02-06 Bicyclo[2.2.1]hept-7-ylamine derivatives and their use as m3 muscarinic receptor modulators WO2008096127A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0702413.6A GB0702413D0 (en) 2007-02-07 2007-02-07 New chemical compounds
GB0702413.6 2007-02-07

Publications (2)

Publication Number Publication Date
WO2008096127A2 WO2008096127A2 (en) 2008-08-14
WO2008096127A3 true WO2008096127A3 (en) 2008-10-23

Family

ID=37898938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/000405 WO2008096127A2 (en) 2007-02-07 2008-02-06 Bicyclo[2.2.1]hept-7-ylamine derivatives and their use as m3 muscarinic receptor modulators

Country Status (2)

Country Link
GB (1) GB0702413D0 (en)
WO (1) WO2008096127A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008149110A1 (en) * 2007-06-08 2008-12-11 Argenta Discovery Limited Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
SI2242759T1 (en) 2008-02-06 2013-01-31 Astrazeneca Ab Compounds
NZ589091A (en) 2008-05-13 2011-07-29 Astrazeneca Ab Quinuclidine derivatives as muscarinic m3 receptor antagonists
CA2760630A1 (en) 2009-04-30 2010-11-04 Teijin Pharma Limited Quaternary ammonium salt compounds
GB0913342D0 (en) * 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
ITRM20110083U1 (en) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire PLATE FOR THE CONSTRUCTION OF TRUCKS FOR AIRPLANES
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592077A1 (en) * 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) * 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
ES2750523T3 (en) 2012-12-18 2020-03-26 Almirall Sa Cyclohexyl and quinuclidinyl carbamate derivatives having beta2-adrenergic agonist and M3 muscarinic antagonist activities
TWI643853B (en) * 2013-02-27 2018-12-11 阿爾米雷爾有限公司 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH β2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES
TW201440768A (en) * 2013-02-27 2014-11-01 Almirall Sa Combinations comprising MABA compounds and corticosteroids
TWI641373B (en) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES
TW201517906A (en) 2013-07-25 2015-05-16 Almirall Sa Combinations comprising MABA compounds and corticosteroids
TW201617343A (en) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 New bicyclic derivatives having [beta]2 adrenergic agonist and M3 muscarinic antagonist activities
JP6963616B2 (en) 2016-12-14 2021-11-10 ベイジン ショウバイ ファーマシューティカル カンパニー，リミティッド Bifunctional compound having a quaternary ammonium salt structure
CN113544121A (en) * 2019-06-06 2021-10-22 中国医药研究开发中心有限公司 Heterocyclic derivative with beta 2 receptor agonistic and M receptor antagonistic activities and medical application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111004A1 (en) * 2004-05-14 2005-11-24 Boehringer Ingelheim International Gmbh Novel sustained-action bronchodilating agents for use in the treatment of respiratory diseases
WO2007017670A1 (en) * 2005-08-08 2007-02-15 Argenta Discovery Ltd. Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
WO2008017824A1 (en) * 2006-08-08 2008-02-14 Argenta Discovery Limited Bicyclo [2. 2. 1] hept-7-ylamine derivatives and their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111004A1 (en) * 2004-05-14 2005-11-24 Boehringer Ingelheim International Gmbh Novel sustained-action bronchodilating agents for use in the treatment of respiratory diseases
WO2007017670A1 (en) * 2005-08-08 2007-02-15 Argenta Discovery Ltd. Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
WO2008017824A1 (en) * 2006-08-08 2008-02-14 Argenta Discovery Limited Bicyclo [2. 2. 1] hept-7-ylamine derivatives and their use

Also Published As

Publication number Publication date
WO2008096127A2 (en) 2008-08-14
GB0702413D0 (en) 2007-03-21

Similar Documents

Publication Publication Date Title
WO2008096127A3 (en) Bicyclo[2.2.1]hept-7-ylamine derivatives and their use as m3 muscarinic receptor modulators
WO2004096757A8 (en) Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
WO2008034736A3 (en) Oxindole derivatives as anticancer agents
WO2007018998A3 (en) Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
WO2005037199A3 (en) Pyrazole derivatives as cannabinoid receptor modulators
MX2009004766A (en) Spiroindolinone derivatives.
WO2006031715A3 (en) Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (sarms)
MX2009012345A (en) 3,3-spiroindolinone derivatives.
HK1146053A1 (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
WO2007084728A3 (en) 2-imino-benzimidazoles
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
WO2009001060A3 (en) Use of compounds for preparing anti-tuberculosis agents
WO2005070893A3 (en) Azadecalin glucocorticoid receptor modulators
WO2004110979A3 (en) Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator
WO2007087488A3 (en) Indole sulfonamide modulators of progesterone receptors
HK1146056A1 (en) Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
HK1146054A1 (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
WO2005118549A3 (en) Compounds having affinity for dopamine d3 receptor and uses thereof
TW200639156A (en) New compounds
WO2008006795A3 (en) Indole compounds
TW200740781A (en) Novel compounds
WO2007130821A3 (en) Mglur5 modulators ii
MY150046A (en) Benzothiazoles as ghrelin receptor modulators
WO2007021711A3 (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08702063

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08702063

Country of ref document: EP

Kind code of ref document: A2